SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.94 CNY | -2.25% |
|
-4.87% | -26.56% |
| Jan. 10 | Kangtai Biological Forecasts Swing to Profit in 2023 | MT |
| 2023 | Shenzhen Kangtai Biological Products Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Shenzhen Kangtai Biological Products Co. specialises in the research, development and marketing of human vaccines. Products include vaccines against hepatitis B, haemophilus influenzae type B, measles and rubella.
Sector
Pharmaceuticals
Calendar
2024-04-22
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
19.94
CNY
Average target price
37.75
CNY
Spread / Average Target
+89.32%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -26.56% | 3.15B | |
| -5.99% | 84.46B | |
| +2.76% | 40.85B | |
| -24.88% | 27.69B | |
| +53.61% | 24.28B | |
| -8.08% | 17.09B | |
| -33.74% | 13.67B | |
| -16.63% | 11.86B | |
| -11.19% | 11.79B | |
| -2.25% | 8.07B |
- Stock Market
- Equities
- 300601 Stock
- News Shenzhen Kangtai Biological Products Co., Ltd.
- Shenzhen Kangtai Biological Products : Kangtai Biological to List 1.3 Million Newly Unlocked Restricted Shares
